secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001628280-26-022385
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio CMO Steven Ryder departs immediately; severance tied to pending Candid merger
--------------------------------------------------------------------------------

- Steven Ryder, M.D., Chief Medical Officer, leaves Rallybio effective March 31, 2026.
- Severance includes payments for without-cause termination; additional contingent on Candid merger close.
- Equity awards remain outstanding and vest per Merger Agreement; exercisable 90 days post-close.
- Pending business combination with Candid Therapeutics announced March 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000162828026022385/0001628280-26-022385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000162828026022385/rlyb-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-022385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer